{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:14:11Z","timestamp":1793110451976,"version":"4.5.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":184,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002632","name":"Hallym University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002632","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jeisys Med Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Melasma is a chronic hyperpigmentary disorder that is difficult to treat in patients with Fitzpatrick phototypes III to VI because of the risk of postinflammatory hyperpigmentation. Radiofrequency microneedling (RFMN) is an emerging modality that targets dermal photoaging while minimizing epidermal injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the clinical effectiveness and safety of POTENZA RFMN in patients with melasma in a real-world retrospective cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors conducted a retrospective pre\u2013post observational study of adults with clinically diagnosed melasma treated with POTENZA (Jeisys Medical Inc., Seoul, Republic of Korea) at a tertiary dermatology center in Seoul, Republic of Korea, between May 2022 and May 2025. All treatments were delivered in bipolar mode at 1\u2005MHz with an insulated microneedle tip (I-25 or I-49). The primary outcome was the change in modified Melasma Area and Severity Index (mMASI) from baseline to posttreatment. Secondary outcomes included physician-rated improvement, patient satisfaction, changes in texture and brightness, and adverse events. Sensitivity analyses were performed to assess the robustness of the findings after excluding patients who received concurrent topical depigmenting agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty patients (mean age 40.7 years; 60% female; Fitzpatrick type III in 80%) were included. Median (interquartile range) mMASI decreased from 6.15 (4.90-8.62) to 3.75 (2.18-5.92) (median \u0394mMASI \u22121.80; median percentage reduction 32.3%; P &amp;lt; .001). A responder analysis using a \u226530% mMASI reduction threshold identified 27\/50 patients (54%) as responders. No significant differences in \u0394mMASI were observed by melasma pattern or Fitzpatrick phototype; however, male patients showed greater median improvement than female patients (\u22122.70 vs \u22121.65; P = .039). In the sunscreen-only subgroup (n = 31, functional monotherapy), the median percentage mMASI reduction was 42.3%, consistent with the overall cohort. Independent reviewers rated clinical improvement in 98% of patients (36% marked, 36% moderate, and 26% slight), and 90% of patients reported satisfaction. Procedure-related adverse events occurred in 12% of cases; all were mild, transient, and resolved without intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>POTENZA RFMN produced clinically meaningful mMASI reductions, high physician-rated improvement, high patient satisfaction, and a favorable safety profile in this predominantly Fitzpatrick type III cohort of patients with mild-to-moderate melasma. These findings support RFMN as a promising adjunctive option and warrant confirmation in prospective controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence: 4 (Risk)<\/jats:title>\n                    <jats:p>For image description, please refer to the figure legend and surrounding text.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/asjof\/ojag143","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:49:23Z","timestamp":1782920963000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Effects and Safety of Radiofrequency Microneedling for the Management of Melasma: A Retrospective Study"],"prefix":"10.1093","volume":"8","author":[{"given":"Han-Bi","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So-Yeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Um","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Yi","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5846-0008","authenticated-orcid":false,"given":"Hye-One","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-9726","authenticated-orcid":false,"given":"Narendra","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"2026071413515148700_ojag143-B1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s40257-024-00863-2","article-title":"An update on new and existing treatments for the management of melasma","volume":"25","author":"Gan","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026071413515148700_ojag143-B2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060824","article-title":"Heterogeneous pathology of melasma and its clinical implications","volume":"17","author":"Kwon","year":"2016","journal-title":"Int J Mol Sci"},{"key":"2026071413515148700_ojag143-B3","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/pcmr.12404","article-title":"Recent progress in melasma pathogenesis","volume":"28","author":"Lee","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"2026071413515148700_ojag143-B4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1590\/abd1806-4841.20143063","article-title":"Melasma: a clinical and epidemiological review","volume":"89","author":"Handel","year":"2014","journal-title":"An Bras Dermatol"},{"key":"2026071413515148700_ojag143-B5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jaad.2009.10.051","article-title":"Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method","volume":"64","author":"Pandya","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2026071413515148700_ojag143-B6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamadermatol.2016.1006","article-title":"Interpretability of the Modified Melasma Area and Severity Index (mMASI)","volume":"152","author":"Rodrigues","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2026071413515148700_ojag143-B7","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1001\/archderm.124.6.869","article-title":"The validity and practicality of sun-reactive skin types I through VI","volume":"124","author":"Fitzpatrick","year":"1988","journal-title":"Arch Dermatol"},{"key":"2026071413515148700_ojag143-B8","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.16669","article-title":"Melasma management: a comprehensive review of treatment strategies including BTX-A","volume":"24","author":"Kania","year":"2025","journal-title":"J Cosmet Dermatol"},{"key":"2026071413515148700_ojag143-B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4103\/jdds.jdds_44_23","article-title":"Melasma in the United States: a cross-sectional study of prevalence data using the all of us database","volume":"27","author":"Verma","year":"2023","journal-title":"J Dermatol Dermatol Surg"},{"key":"2026071413515148700_ojag143-B10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1421499","article-title":"Global research trends on melasma: a bibliometric and visualized study from 2014 to 2023","volume":"15","author":"Wang","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026071413515148700_ojag143-B11","doi-asserted-by":"publisher","first-page":"691","DOI":"10.36849\/JDD.8233","article-title":"The burden of melasma: race, ethnicity, and comorbidities","volume":"23","author":"Sharma","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"2026071413515148700_ojag143-B12","doi-asserted-by":"publisher","DOI":"10.5812\/jssc.120283","article-title":"Melasma: update on epidemiology, clinical presentation, assessment, and scoring","volume":"8","author":"Majid","year":"2022","journal-title":"J Skin Stem Cell"},{"key":"2026071413515148700_ojag143-B13","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1007\/s13555-024-01297-8","article-title":"Melasma: a clinical and epidemiological single-group observational study in the Greek population","volume":"14","author":"Platsidaki","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026071413515148700_ojag143-B14","doi-asserted-by":"publisher","DOI":"10.3390\/biology14101402","article-title":"Unraveling melasma: from epidermal pigmentation to microenvironmental dysregulation","volume":"14","author":"Miao","year":"2025","journal-title":"Biology (Basel)"},{"key":"2026071413515148700_ojag143-B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1337282","article-title":"Different therapeutic approaches in melasma: advances and limitations","volume":"15","author":"Ghasemiyeh","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026071413515148700_ojag143-B16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.23.133","article-title":"Update on melasma treatments","volume":"36","author":"Jo","year":"2024","journal-title":"Ann Dermatol"},{"key":"2026071413515148700_ojag143-B17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jaad.2023.07.1045","article-title":"Best practices in the treatment of melasma with a focus on patients with skin of color","volume":"90","author":"Desai","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2026071413515148700_ojag143-B18","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70845","article-title":"Radiofrequency microneedling for facial rejuvenation: a systematic review","volume":"25","author":"Kumar","year":"2026","journal-title":"J Cosmet Dermatol"},{"key":"2026071413515148700_ojag143-B19","doi-asserted-by":"publisher","DOI":"10.1093\/asjof\/ojag075","article-title":"The efficacy and safety of radiofrequency microneedling for melasma: a systematic review and qualitative evidence synthesis","volume":"8","author":"Kumar","year":"2026","journal-title":"Aesthet Surg J Open Forum"},{"key":"2026071413515148700_ojag143-B20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/DSS.0000000000000888","article-title":"Clinical and histologic effects of fractional microneedling radiofrequency treatment on rosacea","volume":"42","author":"Park","year":"2016","journal-title":"Dermatol Surg"},{"key":"2026071413515148700_ojag143-B21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jocd.13629","article-title":"Efficacy of the combination of Q-switched Nd:YAG laser and microneedling for melasma","volume":"20","author":"Karada\u011f K\u00f6se","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"2026071413515148700_ojag143-B22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.25289\/ML.2017.6.1.17","article-title":"Therapeutic efficacy and safety of invasive pulsed-type bipolar alternating current radiofrequency on melasma and rebound hyperpigmentation","volume":"6","author":"Kim","year":"2017","journal-title":"Med Lasers"},{"key":"2026071413515148700_ojag143-B23","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S601440","article-title":"A retrospective analysis of radiofrequency microneedling for melasma management in the Japanese population","volume":"19","author":"Imaizumi","year":"2026","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2026071413515148700_ojag143-B24","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.70763","article-title":"Exploring the effectiveness, tolerability, and safety of the adjunctive use of microneedling with tranexamic acid in the treatment of melasma","volume":"25","author":"Dhaliwal","year":"2026","journal-title":"J Cosmet Dermatol"},{"key":"2026071413515148700_ojag143-B25","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8350317","article-title":"Evaluation of therapeutic efficacy and safety of tranexamic acid local infiltration in combination with topical 4% hydroquinone cream compared to topical 4% hydroquinone cream alone in patients with melasma: a split-face study","volume":"2018","author":"Tehranchinia","year":"2018","journal-title":"Dermatol Res Pract"},{"key":"2026071413515148700_ojag143-B26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/jocd.12291","article-title":"Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. Topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up","volume":"16","author":"Lajevardi","year":"2017","journal-title":"J Cosmet Dermatol"},{"key":"2026071413515148700_ojag143-B27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ajd.14432","article-title":"Prevention of post-inflammatory hyperpigmentation in skin of colour: a systematic review","volume":"66","author":"Mar","year":"2025","journal-title":"Australas J Dermatol"},{"key":"2026071413515148700_ojag143-B28","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1007\/s13555-022-00728-8","article-title":"Efficacy and safety of using noninsulated microneedle radiofrequency alone versus in combination with polynucleotides for the treatment of melasma: a pilot study","volume":"12","author":"Gulfan","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026071413515148700_ojag143-B29","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41598-023-51133-w","article-title":"Targeting the dermis for melasma maintenance treatment","volume":"14","author":"Han","year":"2024","journal-title":"Sci Rep"},{"key":"2026071413515148700_ojag143-B30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.5021\/ad.2019.31.2.133","article-title":"A face-split study to evaluate the effects of microneedle radiofrequency with Q-switched Nd:YAG Laser for the treatment of melasma","volume":"31","author":"Jung","year":"2019","journal-title":"Ann Dermatol"},{"key":"2026071413515148700_ojag143-B31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10227-004-0158-9","article-title":"Melasma: a review","volume":"8","author":"Victor","year":"2004","journal-title":"J Cutan Med Surg"},{"key":"2026071413515148700_ojag143-B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0733-8635(05)70150-9","article-title":"Disorders of hyperpigmentation","volume":"18","author":"Pandya","year":"2000","journal-title":"Dermatol Clin"},{"key":"2026071413515148700_ojag143-B33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40257-019-00488-w","article-title":"Melasma treatment: an evidence-based review","volume":"21","author":"McKesey","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2026071413515148700_ojag143-B34","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/exd.13915","article-title":"How hormones may modulate human skin pigmentation in melasma: an in vitro perspective","volume":"28","author":"Cario","year":"2019","journal-title":"Exp Dermatol"},{"key":"2026071413515148700_ojag143-B35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1365-4632.2004.02470.x","article-title":"Prevalence and awareness of melasma during pregnancy","volume":"45","author":"Moin","year":"2006","journal-title":"Int J Dermatol"},{"key":"2026071413515148700_ojag143-B36","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1111\/j.1468-3083.2010.03638.x","article-title":"Oestrogen and progesterone receptor expression in melasma: an immunohistochemical analysis","volume":"24","author":"Jang","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026071413515148700_ojag143-B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-026-05834-y","article-title":"Effectiveness of radiofrequency microneedling in the treatment of dermatological conditions: a systematic review","author":"Kumar","year":"2026","journal-title":"Aesthetic Plast Surg"},{"key":"2026071413515148700_ojag143-B38","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/DSS.0000000000003733","article-title":"Radiofrequency and radiofrequency microneedling in skin of color: a review of usage, safety, and efficacy","volume":"49","author":"Syder","year":"2023","journal-title":"Dermatologic Surg"},{"key":"2026071413515148700_ojag143-B39","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.fsc.2019.03.002","article-title":"Radiofrequency microneedling: overview of technology, advantages, differences in devices, studies, and indications","volume":"27","author":"Weiner","year":"2019","journal-title":"Facial Plast Surg Clin North Am"}],"container-title":["Aesthetic Surgery Journal Open Forum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/asjopenforum\/advance-article-pdf\/doi\/10.1093\/asjof\/ojag143\/68695682\/ojag143.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asjopenforum\/article-pdf\/doi\/10.1093\/asjof\/ojag143\/68695682\/ojag143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/asjopenforum\/article-pdf\/doi\/10.1093\/asjof\/ojag143\/68695682\/ojag143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:51:58Z","timestamp":1784051518000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/asjopenforum\/article\/doi\/10.1093\/asjof\/ojag143\/8724717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1093\/asjof\/ojag143","relation":{},"ISSN":["2631-4797"],"issn-type":[{"value":"2631-4797","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"ojag143"}}